Knowing the myeloid-derived suppressor cells: Another enemy of sarcomas patients.

3区 生物学 Q1 Biochemistry, Genetics and Molecular Biology
Daniel J García-Domínguez, Víctor Sánchez-Margalet, Luis de la Cruz-Merino, Lourdes Hontecillas-Prieto
{"title":"Knowing the myeloid-derived suppressor cells: Another enemy of sarcomas patients.","authors":"Daniel J García-Domínguez,&nbsp;Víctor Sánchez-Margalet,&nbsp;Luis de la Cruz-Merino,&nbsp;Lourdes Hontecillas-Prieto","doi":"10.1016/bs.ircmb.2022.11.003","DOIUrl":null,"url":null,"abstract":"<p><p>Sarcomas are heterogeneous and aggressive malignant tumors with variable responses to current standard treatments being usually incurable for those patients with metastatic and unresectable diseases. The lack of curative strategies has led to develop new therapies in the treatment of sarcomas where the role of immune system is an evolving field. Most sarcomas often exhibit an immunosuppressive microenvironment, which reduces their capacity to trigger an immune response. Therefore, sarcomas are broadly considered as an \"immune cold\" tumor, although some studies have described a great immune heterogeneity across sarcoma subtypes. Sarcoma cells, like other tumors, evade their immune destruction through a variety of mechanisms, including expansion and recruitment of myeloid derived suppressor cells (MDSCs). MDSCs are immature myeloid cells that have been correlated with a reduction of the therapeutic efficacy, including immunotherapy, tumor progression and worst prognosis. Consequently, different strategies have been developed in recent years to target MDSCs in cancer treatments. This chapter discusses the role of MDSCs in sarcomas and their current potential as a therapeutic target in these malignancies.</p>","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":"375 ","pages":"93-116"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International review of cell and molecular biology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/bs.ircmb.2022.11.003","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Sarcomas are heterogeneous and aggressive malignant tumors with variable responses to current standard treatments being usually incurable for those patients with metastatic and unresectable diseases. The lack of curative strategies has led to develop new therapies in the treatment of sarcomas where the role of immune system is an evolving field. Most sarcomas often exhibit an immunosuppressive microenvironment, which reduces their capacity to trigger an immune response. Therefore, sarcomas are broadly considered as an "immune cold" tumor, although some studies have described a great immune heterogeneity across sarcoma subtypes. Sarcoma cells, like other tumors, evade their immune destruction through a variety of mechanisms, including expansion and recruitment of myeloid derived suppressor cells (MDSCs). MDSCs are immature myeloid cells that have been correlated with a reduction of the therapeutic efficacy, including immunotherapy, tumor progression and worst prognosis. Consequently, different strategies have been developed in recent years to target MDSCs in cancer treatments. This chapter discusses the role of MDSCs in sarcomas and their current potential as a therapeutic target in these malignancies.

了解髓源性抑制细胞:肉瘤患者的另一个敌人。
肉瘤是异质性和侵袭性恶性肿瘤,对目前标准治疗的反应不同,对于那些转移性和不可切除疾病的患者通常是无法治愈的。治疗策略的缺乏导致了肉瘤治疗的新疗法的开发,其中免疫系统的作用是一个不断发展的领域。大多数肉瘤通常表现出免疫抑制微环境,这降低了它们触发免疫反应的能力。因此,肉瘤被广泛认为是一种“免疫冷”肿瘤,尽管一些研究描述了肉瘤亚型之间存在很大的免疫异质性。与其他肿瘤一样,肉瘤细胞通过多种机制逃避免疫破坏,包括骨髓源性抑制细胞(MDSCs)的扩增和募集。MDSCs是未成熟的髓样细胞,与治疗效果降低相关,包括免疫治疗、肿瘤进展和最差预后。因此,近年来开发了不同的策略来靶向MDSCs用于癌症治疗。本章讨论了MDSCs在肉瘤中的作用以及它们目前作为这些恶性肿瘤治疗靶点的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International review of cell and molecular biology
International review of cell and molecular biology BIOCHEMISTRY & MOLECULAR BIOLOGY-CELL BIOLOGY
CiteScore
7.70
自引率
0.00%
发文量
67
审稿时长
>12 weeks
期刊介绍: International Review of Cell and Molecular Biology presents current advances and comprehensive reviews in cell biology-both plant and animal. Articles address structure and control of gene expression, nucleocytoplasmic interactions, control of cell development and differentiation, and cell transformation and growth. Authored by some of the foremost scientists in the field, each volume provides up-to-date information and directions for future research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信